Premium
Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation
Author(s) -
Ohata Yasuhisa,
Ohta Hideaki,
Hashii Yoshiko,
Tokimasa Sadao,
Ozono Keiichi,
Hara Junichi
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21774
Subject(s) - medicine , hematopoietic stem cell transplantation , dosing , chemotherapy , trimethoprim , pneumocystis pneumonia , pneumonia , transplantation , regimen , surgery , sulfamethoxazole , pneumocystis jirovecii , antibiotics , microbiology and biotechnology , biology
Abstract Pneumocystis jiroveci pneumonia (PCP) is a serious complication in patients receiving chemotherapy or hematopoietic stem cell transplantation. Current recommendations for trimethoprim‐sulfamethoxazole (TMP‐SMZ) dosing as PCP prophylaxis in immunocompromised patients are based on either daily dosing or dosing three consecutive days per week. We report our experience of prophylaxis with TMP‐SMZ twice daily on two non‐consecutive days per week in 145 immunocompromised children with hematologic disorders, cancer, or metabolic disorders following chemotherapy or hematopoietic stem cell transplantation. There were no breakthrough cases of PCP. We therefore conclude our prophylaxis regimen is effective against PCP in immunocompromised children. Pediatr Blood Cancer 2009;52:142–144. © 2008 Wiley‐Liss, Inc.